COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO (NB-UVB)

Dr ayesha wahid

Status and phase: Invitation-only; Early Phase 1

Conditions: Tacrolimus; Vitiligo - Macular Depigmentation

Treatments: Drug: Calcipotriol; Drug: Tacrolimus

Study type: Interventional

Funder types: Other

Identifiers

NCT06880042

LGH

Details and patient eligibility

About

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Full description

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

Enrollment: 60 estimated patients

Sex: All

Ages: 15 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months

Exclusion criteria

• • Pregnant or lactating female patients.

  • Skin malignancy or any other malignant skin condition.
  • Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
  • Prior history of allergy to tacrolimus or calcipotriol.
  • Other form of treatment for vitiligo within at least 1 month.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Tacrolimus

Active Comparator group

Description:

Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB

Treatment:

Drug: Tacrolimus

Calcipotriol

Active Comparator group

Description:

Calcipotriol is a vitamin D analogue that will act as immunomodulator

Treatment:

Drug: Calcipotriol